Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

An overview of reviews with network meta-analyses comparing disease-modifying therapies for relapsing multiple sclerosis.

Autor: Drudge, Christopher, Samjoo, Imtiaz A, Brennan, Róisín, Badgujar, Lohit, Khurana, Vivek, Tiwari, Santosh, Adlard, Nicholas, Banhazi, Judit

Publikováno v: Future Neurology; Oct2023, Vol. 18 Issue 3, p1-18, 18p

Systematic review and network meta‐analysis comparing ofatumumab with other disease‐modifying therapies available in Japan for the treatment of patients with relapsing multiple sclerosis.

Autor: Drudge, Christopher, Zhao, Melody, Tanaka, Satoru, Tanaka, Nozomu, Otaka, Hiromichi, Kawachi, Izumi, Häring, Dieter A., Brennan, Róisín, Adlard, Nicholas, Samjoo, Imtiaz A.

Publikováno v: Clinical & Experimental Neuroimmunology; Nov2022, Vol. 13 Issue 4, p234-245, 12p

Does the Multiple Sclerosis Impact Scale-29 (MSIS-29) have the range to capture the experience of fully ambulatory multiple sclerosis patients? Learnings from the ASCLEPIOS studies.

Autor: Regnault A; Modus Outcomes, Lyon, France., Loubert A; Modus Outcomes, Lyon, France., Brennan R; Novartis Pharma AG, Basel, Switzerland., Meunier J; Modus Outcomes, Lyon, France., Naujoks C; Novartis Pharma AG, Basel, Switzerland., Cano S; Modus Outcomes, Letchworth Garden City, UK., Adlard N; Novartis Pharma AG, Basel, Switzerland.

Publikováno v: Multiple sclerosis journal - experimental, translational and clinical [Mult Scler J Exp Transl Clin] 2023 Sep 28; Vol. 9 (3), pp. 20552173231201422. Date of Electronic Publication: 2023 Sep 28 (Print Publication: 2023).